LNAI

Lunai Bioworks Inc. (LNAI) - 10-Q Summary

Business Context and Reporting Period

This summary covers the quarterly period ended March 31, 2026. Lunai Bioworks Inc. (formerly Renovaro Inc.) is an AI-driven biotechnology company focused on precision medicine, biomarker discovery, and therapeutic development. The company operates through two primary segments: Renovaro Biosciences (RENB), developing allogeneic cell and gene therapies for oncology and infectious diseases, and BioSymetrics, an AI platform for biomedical data integration. During the period, the company deconsolidated its subsidiary Gedi Cube B.V. following its bankruptcy declaration in September 2025.

Key Financial Metrics

Note: Revenue is derived from a single research services contract with Kapoose Creek Bio. There is no Cost of Goods Sold.

Material Changes vs. Prior Period

• Revenue: The company recognized $20,942 in service revenue for the three and nine months ended March 31, 2026, compared to $0 in the prior year periods.
• Operating Expenses: Total operating expenses decreased significantly by 65% ($2.7M) for the quarter and 89% ($55.5M) for the nine-month period compared to the prior year. This reduction is primarily due to the absence of a $47.6M goodwill impairment charge recorded in the prior year and reduced general and administrative costs.
• Net Loss Improvement: The nine-month net loss decreased by 97% to $(1.55M) from $(51.3M) in the prior year. This improvement was driven by the gain on the bankruptcy of a subsidiary ($12.0M), the absence of prior-year goodwill impairments, and reduced operating expenses, partially offset by a $7.4M loss on debt extinguishment.
• Liquidity: Cash increased from $92,700 at June 30, 2025, to $3.16M at March 31, 2026, primarily due to financing activities including an ATM offering ($4.5M) and private placements ($750k).

Guidance, Outlook, Risks, and Unusual Items

• Going Concern: The filing explicitly states substantial doubt about the company's ability to continue as a going concern due to recurring losses, a working capital deficit of $15.55M, and dependence on additional financing. Management plans to secure funding through equity or debt, though no assurance is provided.
• Unusual Items:
  • Gain on Bankruptcy: A non-cash gain of $12.0M was recognized from the deconsolidation of Gedi Cube B.V.
  • Debt Extinguishment: The company recorded a $7.4M loss on extinguishment of debt during the nine-month period, related to exchanging secured notes for convertible notes and equity.
• Legal Proceedings: The company is involved in multiple significant legal matters, including a pending securities class action (Chow Action) where a settlement is awaiting final court approval, and derivative litigation (Koenig-Solak-Midler Settlement) also pending approval. Additionally, the company is suing former partners (Gumrukcu/Wittekind) alleging fraud regarding study results, with a trial reset for November 2026.
• Subsequent Events:
  • Acquired Neurobridge IP Holdings for $20M in Series B Convertible Preferred Stock (May 1, 2026).
  • Stockholders approved a further reverse stock split (1-for-3 to 1-for-30) on May 8, 2026.
  • Filed a civil action against alleged naked short sellers on May 11, 2026.

Investor Verification Checklist

• Capital Runway: Verify the sufficiency of the $3.16M cash balance against the $15.55M working capital deficit and ongoing burn rate.
• Debt Structure: Review the terms of remaining convertible notes and related party debt, specifically the $871k owed to related parties and $120k in convertible notes.
• Legal Settlements: Monitor the final court approval status of the Securities Class Action and Derivative Litigation settlements to determine potential cash outflows.
• Revenue Sustainability: Assess the scalability of the $20,942 revenue stream from a single customer and the timeline for product commercialization.
• Dilution Risk: Evaluate the impact of the recent Series B Preferred Stock issuance ($20M value) and the approved reverse stock split on existing shareholders.